Abstract Objective To investigate the effects of rapamycin (RAP) on pulmonary hypertension (PH) in rats, and to provide new insights into medication selection for the clinical treatment of PH. Methods Fifty male Sprague-Dawley rats were randomly divided into blank control, PH model, solvent control, RAP 1, and RAP 2 groups. A rat model of PH was induced by left pneumonectomy (PE) and monocrotaline (MCT). At 5 days after PH model establishment, the solvent control group and the RAP 1 group received an intramuscular injection of solvent and RAP, respectively. At 35 days after PH model establishment, the RAP 2 group received an intramuscular injection of RAP. The mean pulmonary artery pressure (mPAP) and the right ventricle/left ventricle plus septum weight ratio (RV/LV+S) were measured in each group. Histopathological changes in the right lung were evaluated by hematoxylin-eosin (HE) staining. The relative expression of alpha-smooth muscle actin (α-SMA) and smooth muscle protein 22-alpha (SM22α) in each group was determined using real-time PCR. Results At 35 days after surgery, the PH model and the solvent control groups had significantly higher mPAP and RV/LV+S than the blank control group, while the RAP 1 and the RAP 2 groups had significantly lower mPAP than the solvent control group (P<0.05). The RV/LV+S in the RAP 1 group was significantly lower than that in the solvent control group (P<0.05); however, there was no significant difference in RV/LV+S between the RAP 2 and the solvent control groups (P>0.05). HE staining in the right lung showed the substantially thickened pulmonary artery wall and narrowed arterial lumen in the PH model and the solvent control groups compared with the blank control group. Different degrees of reversal of the pulmonary artery wall thickening were observed after RAP administration. The results of real-time PCR revealed that the relative expression of α-SMA and SM22α in the PH model and the solvent control groups was significantly lower than in the blank control group, while the relative expression of α-SMA and SM22α in the RAP 1 and the RAP 2 groups was significantly higher than in the solvent control group (P<0.05). Conclusions RAP can reverse the increase in pulmonary artery pressure and the right ventricular hypertrophy probably by regulation of the phenotypic conversion of vascular smooth muscle cells.
Ma XM, Blenis J. Molecular mechanisms of mtor-mediated translational control[J]. Nat Rev Mol Cell Biol, 2009, 10(5): 307-318.
[3]
Bozkurt B, Karakaya G, Kalyoncu AF. Seasonal rhinitis, clinical characteristics and risk factors for asthma[J]. Int Arch Allergy Immunol, 2005, 138(1): 73-79.
[16]
Laplante M, Sabatini DM. Mtor singnaling at a glance[J]. J Cell Sci, 2009, 122(pt 20): 3589-3594.
[17]
Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of akt/pkb by the rictor-mtor complex[J]. Science, 2005, 307(5712): 1098-1101.
[18]
Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mtorc components reptor, rictor, or mlst8 reveals that mtorc2 is required for signaling to akt-foxo and pkcalpha, but not s6k1[J]. Dev Cell, 2006, 11(6): 859-871.
[19]
Han M, Dong LH, Zheng B, et al. Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling[J]. Life Sci, 2009, 84(13-14): 394-401.
[4]
Homburger HA. Diagnosing allergic diseases in children. Practical recommendations for consulting pathologists[J]. Arch Pathol Lab Med, 2004, 128(9): 1028-1031.
[5]
Beydon N, Davis SD, Lombardi E, et al. An Official American Thoracic Society/European Respiratory Society Statement: Pulmonary Function Testing in Preschool Children [J]. Am J Respir Crit Care Med, 2007, 175(12): 1304-1345.
[20]
Fan Z, Li C, Qin C, et al. Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscles cells [J]. DNA Cell Biol, 2014, 33(1): 12-19.
[6]
American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide[J]. Am J Respir Crit Med, 2005, 171(8): 912-930.
Rensen SS, Doevendans PA, Van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotype diversity[J]. Neth Heart J, 2007, 315(3): 100-108.
[8]
Thompson PJ, Salvi S, Lin J, et al. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong[J]. Respirology, 2013, 18(6): 957-967.
